CRSP

CRISPR Therapeutics AG (CRSP) closed at $49.39, down 1.2% and underperforming the S&P 500's 0.52% loss. The stock has declined 10.25% over the past month, significantly underperforming the Medical sector's 3.23% gain.

While revenue projections show strong growth of 1017.42% for the upcoming quarter and 824.53% for the full year, the company remains unprofitable with projected EPS of -$1.07 and -$4.48 respectively. CRSP holds a Zacks Rank of #4 (Sell).

CRISPR Therapeutics (CRSP) has attracted significant investor attention but faces headwinds. The stock declined 10.3% over the past month, underperforming the S&P 500.

While the company shows strong revenue growth projections (824.5% for current fiscal year), it carries a Zacks Rank #4 (Sell) rating due to negative earnings estimates and premium valuation relative to peers. The company is expected to turn profitable next fiscal year with projected EPS of $3.64.

CRISPR Therapeutics has transitioned to a commercial biotech with its approved gene-editing therapy Casgevy for blood disorders. The company has several promising pipeline candidates including CTX310 for cholesterol/triglycerides, zugo-cel for autoimmune diseases and blood cancers, and CTX611 as an anticoagulant. While significant clinical and commercial progress could drive substantial stock gains by 2030, investors face considerable risks including potential clinical trial failures and uncertain profitability economics for one-time gene-editing treatments.

Cathie Wood's ARK Invest purchased $3.4 million worth of CRISPR Therapeutics stock on consecutive trading days (Oct. 9 and Oct. 12), bringing her total holdings to $379.1 million. The investment reflects confidence in CRISPR's approved therapy Casgevy and promising pipeline candidates CTX-310 and CTX611, despite the stock declining 25% over the past year. CRISPR reported strong Q2 revenue growth of 151% year-over-year and maintains $2.36 billion in cash.

CRISPR Therapeutics AG stock fell 4.48% on October 16, 2026, significantly underperforming the S&P 500's 1.09% decline. The stock has depreciated 10.13% over the past month, lagging the Medical sector's 2.68% gain. While analysts expect strong revenue growth of 1017.42% year-over-year for the upcoming quarter, the company maintains a Zacks Rank of #3 (Hold) with a slight 0.22% downward revision to consensus EPS estimates.

Matchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.

CRISPR Therapeutics AG (CRSP) declined 3.45% to $51.55, underperforming the S&P 500's 0.06% loss. Despite a 3.23% monthly gain, the stock faces headwinds.

The company is expected to report an EPS of -$1.06 but projects significant revenue growth of 971.24% year-over-year. CRSP holds a Zacks Rank #2 (Buy) rating, though its industry ranks in the bottom 33% of all sectors.

CRISPR Therapeutics (CRSP) has been trending on Zacks.com with shares returning +3.2% over the past month, outperforming the S&P 500's +2.4% gain. The company received a Zacks Rank #2 (Buy) rating based on stable earnings estimates and strong revenue growth forecasts (+971.2% for current quarter).

However, the stock is trading at a premium valuation (F grade) compared to peers. The company is expected to turn profitable next fiscal year with EPS of $3.61.

CRISPR Therapeutics AG (CRSP) declined 5.82% to $54.00, underperforming the broader market gains. Despite a 2.78% monthly gain, the stock faces headwinds from its Medical sector's 4.26% loss. Upcoming earnings are expected to show an EPS of -$1.06 with significant revenue growth of 971.24% year-over-year, though the company maintains a Zacks Rank #3 (Hold) rating.

CRISPR Therapeutics (CRSP) has attracted investor attention with significant revenue growth projections (+771.5% for current fiscal year) and improving earnings estimates. However, the company is rated Zacks Rank #3 (Hold) and trades at a premium valuation (F grade) compared to peers. The stock is expected to perform in line with the broader market in the near term.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline.

Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Roche announced encouraging one-year data from phase III studies showing vamikibart delivered sustained vision gains and reduced macular thickness in uveitic macular edema patients. The FDA accepted the drug's BLA with a decision expected by July 2027.

If approved, vamikibart would be the first non-steroid targeted treatment for this sight-threatening condition. Roche is also advancing pipeline candidates including fenebrutinib for multiple sclerosis, sefaxersen for IgA nephropathy, and enicepatide for type 2 diabetes.

AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline.

Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing.